Pharming Group N.V. - Ads Each Representing 10 (PHAR) closed at $9.65 on October 21, 2026, down 1.0% from the previous close, on volume of 10,739 shares (30-day average 26,758).
Data as of October 21, 2026.
Seeking Alpha News (Thu, 22-Oct 1:47 AM ET)
Pharming Group announces third quarter 2026 revenues above market expectations
Globe Newswire (Thu, 22-Oct 1:00 AM ET)
Globe Newswire (Wed, 14-Oct 2:00 AM ET)
Pharming announces CEO transition
Globe Newswire (Tue, 29-Sep 1:00 AM ET)
Globe Newswire (Fri, 25-Sep 10:30 AM ET)
Globe Newswire (Tue, 22-Sep 1:00 AM ET)
FDA approves Pharming's Joenja as first treatment for children with APDS in the U.S.
Globe Newswire (Fri, 11-Sep 1:59 PM ET)
Pharming Group to participate in September investor conferences
Globe Newswire (Wed, 9-Sep 2:00 AM ET)
Globe Newswire (Thu, 13-Aug 1:00 AM ET)
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
PRNewswire (Fri, 7-Aug 10:05 AM ET)
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Pharming Group N.V. - Ads Each Representing 10 trades on the NASDAQ stock market under the symbol PHAR.
As of October 21, 2026, PHAR stock price declined to $9.65 with 10,739 million shares trading.
PHAR has a beta of 0.26, meaning it tends to be less sensitive to market movements. PHAR has a correlation of 0.00 to the broad based SPY ETF.
PHAR has a market cap of $683.01 million. This is considered a Small Cap stock.
Last quarter Pharming Group N.V. - Ads Each Representing 10 reported $90 million in Revenue and $.02 earnings per share. This fell short of revenue expectation by $-11 million and missed earnings estimates by -$.07.
In the last 3 years, PHAR traded as high as $21.34 and as low as $6.65.
PHAR has underperformed the market in the last year with a return of -32.1%, while the SPY ETF gained +16.3%. In the last 3 month period, PHAR fell short of the market, returning -26.4%, while SPY returned +4.4%. However, in the most recent 2 weeks PHAR has outperformed the stock market by returning -0.3%, while SPY returned -0.8%.
PHAR support price is $9.45 and resistance is $10.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHAR shares will trade within this expected range on the day.
